Nouvelle déclaration d'incident
No de la demande: 2021-2654
Numéro de référence du titulaire d'homologation: 2020-CA-000096
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: CANADA
État: ALBERTA
ARLA No d'homologation 29930 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Hartz UltraGuard OneSpot Flea and Tick Cat Drops
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Professionnel de la santé
Cat / Chat
Domestic Shorthair
1
Femme
1
2.5
kg
Cutanée
Orale
>24 hrs <=3 days / >24 h <=3 jours
<=30 min / <=30 min
Système
Unknown / Inconnu
Non
Inconnu
Unknown/Inconnu
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 04-May-2020, a 1 year old, 2.5 kilogram, intact, female, Domestic Shorthair cat, in good condition, with no known concomitant medical conditions, was administered 1 dose of Hartz UltraGuard OneSpot Flea and Tick Cat Drops (S Methoprene) via the topical route by the animal owner. Immediately post application the cat ingested a small amount of the product and developed hypersalivation, anorexia, and lethargy. At an unknown time post application, the cat developed episodes of staring (abnormal behaviour) and paddling (convulsions), and application site irritation and alopecia. An unknown amount of unspecified triple antibiotic ointment was applied to the application site via the topical route by the animal owner. On 06-May-2020, the cat was evaluated by a veterinarian and exhibited lethargy, mild tachypnea, and an application site lesion with alopecia, thickened skin with erythematous edges and discolouration was noted. It was unclear to the veterinarian if neurological signs (staring and paddling) were actually observed by the owner or reported only after the owner was asked if those signs occurred. The cat was bathed using an unspecified shampoo. No additional information was received in this case.
Modérée
Assessment: S-methoprene has a very wide margin of safety in cats and is not known to cause neurological signs like paddling or convulsions. Even if ingested, only mild GI upset would be expected. Other causes for the neurological signs should be considered including misinterpretation of behavioural changes as paddling or convulsions, exposure to another product or product misidentification. Dermal signs, such as those described, are possible if a pet is sensitive to any of the product's active or inactive ingredients. The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.